Drug Profile
DOV 216303
Alternative Names: DOV 216,303Latest Information Update: 21 Apr 2008
Price :
$50
*
At a glance
- Originator Wyeth
- Developer DOV Pharmaceutical
- Class Antidepressants; Chlorobenzenes; Pyrrolidines; Small molecules
- Mechanism of Action Adrenergic receptor antagonists; Dopamine uptake inhibitors; Serotonin uptake inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Major depressive disorder
Most Recent Events
- 07 Dec 2006 Merck and DOV Pharmacueticals terminate their licensing agreement for DOV 216303; DOV regains all rights
- 05 Oct 2005 Data from a media release have been added to the adverse events and Affective disorders therapeutic trials sections
- 09 Aug 2004 Merck licensed the exclusive worldwide rights to DOV 216303 for the treatment of depression, anxiety and addiction